Funding from Cancer Prevention and Research Institute of Texas has brought more than 324 distinguished cancer researchers to Texas.
Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with ...
The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...
The University of Texas MD Anderson Cancer Center today was awarded nearly $23 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of 20 cancer research projects to ...
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult ...
Utrecht, The Netherlands Thursday, February 20, 2025, 15:00 Hrs [IST] ...
These useful findings assigned a novel functional implication of histone acylation, crotonylation. Although the mechanistic insights have been provided in great detail regarding the role of the YEATS2 ...
Purple Biotech has entered a Phase II trial with its small molecule drug, NT219, focusing on patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback